Over 80 anesthesia clinicians have collectively invested over $5 million in Expanesthetics. For a limited time, you can join them for less than $10,000. Click here to learn more.
Modern surgery would not be possible without general anesthesia. Yet, vital as they are, all general anesthetics until now have caused many side effects that require a specialized anesthesia clinician to manage. Expanesthetics is using a groundbreaking scientific discovery to develop new inhaled general anesthetics with fewer side effects.
Expanesthetics has built a global network of partners to execute our world-leading research. We have conducted R&D on four continents, our work has attracted the attention of pioneers in drug development all over the world, and the majority of our shareholders are anesthesia clinicians.
Expanesthetics has also discovered a class of compounds within our anesthesia program that appears to have great potential for pain relief. With the opioid crisis claiming far too many lives in our communities, the need for new breakthroughs in pain relief has never been clearer.